3.38
Precedente Chiudi:
$3.19
Aprire:
$3.1938
Volume 24 ore:
19,947
Relative Volume:
0.59
Capitalizzazione di mercato:
$19.35M
Reddito:
$257.00K
Utile/perdita netta:
$-3.07M
Rapporto P/E:
-3.5478
EPS:
-0.9527
Flusso di cassa netto:
$-1.40M
1 W Prestazione:
-15.92%
1M Prestazione:
-31.02%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Optimi Health Corp Stock (OPTH) Company Profile
Compare OPTH vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
OPTH
Optimi Health Corp
|
3.38 | 19.35M | 257.00K | -3.07M | -1.40M | -0.9527 |
|
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Optimi Health Corp Borsa (OPTH) Ultime notizie
Optimi Health to Present at the ThinkEquity Conference - GlobeNewswire Inc.
Optimi Health Corp. (OPTI.CN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial - mugglehead.com
Optimi Health Corp. Common Shares (NASDAQ: OPTH) Stock Price, News & Analysis - kalkine.com.au
Optimi Health Corp. Plans Health Canada-Authorized Phase 3 Trial of MDMA-Assisted Therapy for PTSD - Quiver Quantitative
Optimi Health Corp Share PriceOPTI, RNS News, Articles, Quotes, & Charts (CNSX:OPTI) - Proactive financial news
OPTI: Commercially supplying natural psychedelics, expanding globally as regulations advance - TradingView
Optimi Health at H.C. Wainwright conference: early lead in psychedelics - Investing.com
OPTI: Commercial psychedelic manufacturer expands globally as regulatory momentum accelerates - TradingView
Optimi Health Corp. (CN:OPTI) Advances as Psychedelic Medicine Pipeline and Clinical Expansion Improve Investor Sentiment - kalkine.ca
Optimi Health plans phase 2 psilocybin trial for depression By Investing.com - Investing.com Nigeria
Optimi Health plans phase 2 psilocybin trial for depression By Investing.com - Investing.com South Africa
OPTH Stock Price, Quote & News - Syfe
OPTH Looks 64.2% Overvalued on GF Value™ - GuruFocus
Optimi Health Launches Health Canada-Authorized Phase 2 Psilocybin Trial for Major Depressive Disorder - kalkine.ca
Optimi Health plans phase 2 psilocybin trial for depression By Investing.com - Investing.com Canada
Optimi Health To Initiate Phase 2 Psilocybin Trial For Major Depression - RTTNews
Optimi Health plans phase 2 psilocybin trial for depression - Investing.com
Optimi Health CorpTrial Initiation Planned For H1 2027, Dosing To Complete By End Of 2027 - TradingView
Optimi Health plans phase 2 psilocybin trial for depression By Investing.com - Investing.com India
Optimi Health Announces Health Canada-Authorized Phase 2 Trial of Natural Psilocybin for Major Depressive Disorder - Quiver Quantitative
A 200-person psilocybin depression trial is coming from Optimi Health (OPTH); here’s when and where - Stock Titan
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder - Yahoo Finance
Optimi Health Stock Under Pressure: Can Psychedelic Growth Overcome Rising Execution and Funding Risks? - kalkine.ca
Optimi Health to Present at H.C. Wainwright Global Investment Conference - TipRanks
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Optimi Health Corp. to Present at H.C. Wainwright 28th Annual Global Investment Conference in September 2026 - kalkine.ca
Psychedelic-drug maker Optimi Health (OPTH) plans investor meetings in New York - Stock Titan
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Optimi Health Stock Faces Renewed Pressure as Psychedelic-Sector Sentiment Weakens - kalkine.ca
Optimi Health (CN:OPTI) Drops 4.12% as Revenue Weakness, Funding Risk and Psychedelic-Sector Uncertainty Pressure Sentiment - kalkine.ca
Optimi Health Corp (CN: OPTI) Share Price, OPTI Stock News, OPTI Share Price & Updates - kalkine.ca
Optimi Health (OPTH) lines up discounted share funding with new $100M facility - Stock Titan
Optimi Health Corp. Common Shares (NASDAQ: OPTH) Stock Price, News & Analysis - kalkine.ca
Optimi Health Corp. SEC Filing (Aug 26, 2026) - Stock Titan
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now - Yahoo! Finance Canada
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now - Yahoo Finance
Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances - Yahoo Finance
Optimi Health (OPTH) Stock Chart and Price History 2026 - MarketBeat
Optimi Health Sets Up US$100 Million Equity Line for Psychedelic Drug Expansion - TipRanks
Optimi Health (OPTH) clears way for resale of shares over 3x its float - Stock Titan
Optimi Health (OPTH) secures US$100M equity line with convertible note sweeteners - Stock Titan
Optimi Health Corp. Establishes US$100 Million Discretionary Equity Line of Credit with Seven Knots - kalkine.ca
Optimi Health (OPTH) raises $20.7M, posts larger loss and builds cash buffer - Stock Titan
Optimi Health Corp. Announces Up to US$100 Million Equity Line of Credit with Seven Knots | OPTH Stock News - Quiver Quantitative
Optimi Health Establishes Discretionary Equity Facility - Yahoo Finance
Optimi Health Corp. Announces Up to US$100 Million Equity Line of Credit with Seven Knots - Quiver Quantitative
Optimi Health Establishes Discretionary Equity Facility - globenewswire.com
Norton Rose Fulbright advises Optimi Health on equity facility - Norton Rose Fulbright
Norton Rose Fulbright advises Optimi Health on equity facility - Norton Rose Fulbright
Optimi Health Corp Azioni (OPTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):